Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
2006 3
2008 2
2009 4
2010 3
2011 3
2012 3
2013 3
2014 1
2015 1
2016 1
2018 2
2019 3
2020 8
2021 17
2022 11
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
Advances in Lymphoma Molecular Diagnostics.
Kos IA, Thurner L, Bittenbring JT, Christofyllakis K, Kaddu-Mulindwa D. Kos IA, et al. Among authors: kaddu mulindwa d. Diagnostics (Basel). 2021 Nov 23;11(12):2174. doi: 10.3390/diagnostics11122174. Diagnostics (Basel). 2021. PMID: 34943410 Free PMC article. Review.
Current Treatment Options in CLL.
Bewarder M, Stilgenbauer S, Thurner L, Kaddu-Mulindwa D. Bewarder M, et al. Among authors: kaddu mulindwa d. Cancers (Basel). 2021 May 19;13(10):2468. doi: 10.3390/cancers13102468. Cancers (Basel). 2021. PMID: 34069354 Free PMC article. Review.
Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review).
Christofyllakis K, Bittenbring JT, Thurner L, Ahlgrimm M, Stilgenbauer S, Bewarder M, Kaddu-Mulindwa D. Christofyllakis K, et al. Among authors: kaddu mulindwa d. Mol Clin Oncol. 2022 Jan;16(1):21. doi: 10.3892/mco.2021.2453. Epub 2021 Nov 25. Mol Clin Oncol. 2022. PMID: 34909199 Free PMC article. Review.
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study.
Thurner L, Ziepert M, Berdel C, Schmidt C, Borchmann P, Kaddu-Mulindwa D, Viardot A, Witzens-Harig M, Dierlamm J, Haenel M, Metzner B, Wulf G, Lengfelder E, Keller UB, Frickhofen N, Nickelsen M, Gaska T, Griesinger F, Mahlberg R, Marks R, Shpilberg O, Lindemann HW, Soekler M, Fischer von Weikersthal L, Kiehl M, Roemer E, Bentz M, Krammer-Steiner B, Trappe R, de Nully Brown P, Federico M, Merli F, Engelhard M, Glass B, Schmitz N, Truemper L, Bewarder M, Hartmann F, Murawski N, Stilgenbauer S, Rosenwald A, Altmann B, Schmidberger H, Fleckenstein J, Loeffler M, Poeschel V, Held G. Thurner L, et al. Among authors: kaddu mulindwa d. Hemasphere. 2023 Jul 5;7(7):e904. doi: 10.1097/HS9.0000000000000904. eCollection 2023 Jul. Hemasphere. 2023. PMID: 37427146 Free PMC article.
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
Kaddu-Mulindwa D, Gödel P, Kutsch N, Heger JM, Scheid C, Borchmann P, Holtick U, Held G, Thurner L, Bewarder M, Rixecker T, Bittenbring JT. Kaddu-Mulindwa D, et al. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e498-e506. doi: 10.1016/j.clml.2022.01.007. Epub 2022 Jan 13. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35094950 Review.
Ars2-containing bispecific, Fab- and IgG1-format BAR-bodies to target DLBCL cells.
Kiefer M, Thurner L, Bock T, Cetin O, Kos I, Lesan V, Kaddu-Mulindwa D, Bittenbring JT, Fadle N, Regitz E, Hoth M, Neumann F, Preuss KD, Pfreundschuh M, Christofyllakis K, Bewarder M. Kiefer M, et al. Among authors: kaddu mulindwa d. EJHaem. 2022 Dec 27;4(1):125-134. doi: 10.1002/jha2.635. eCollection 2023 Feb. EJHaem. 2022. PMID: 36819155 Free PMC article.
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
Kaddu-Mulindwa D, Lesan V, Berdel C, Stilgenbauer S, Bewarder M, Thurner L, Witzens-Harig M, Viardot A, Soekler M, Keller U, Truemper L, Christofyllakis K, Fleser O, Bittenbring JT, Poeschel V, Held G, Jagoda P. Kaddu-Mulindwa D, et al. Leuk Lymphoma. 2022 Feb;63(2):326-334. doi: 10.1080/10428194.2021.1975193. Epub 2021 Oct 20. Leuk Lymphoma. 2022. PMID: 34668817
63 results